Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non-HDL cholesterol and LDL cholesterol

Journal of Internal Medicine

Volumn 268, Issue 6, 2010, Pages 549-551

  Walldius, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL PRACTICE; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; NOTE; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

APOLIPOPROTEINS B; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 78649487477     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02286.x     Document Type: Note

References (12)

1. McQueen MJ, Hawken S, Wang X et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-33.
2. Parish S, Peto R, Palmer A et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Europ Heart J 2009; 30: 2137-46.
3. Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/tencountry panel. J Internal Med 2006; 259: 247-58.
4. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
5. Sniderman AD, Furberg CD, Keech A et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-80.
6. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006; 259: 493-519.
7. Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2008; 264: 30-8
8. Holewijn S, Den Heijer M, Swinkels DW, Stalenhoef AFH, De Graaf J. Apolipoprotein B, non-HDL-cholesterol and LDL cholesterol in identifying individuals at increased cardiovascular risk. J Intern Med, this volume.
9. Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
10. Ahmad J, Khan AR, Ahmed F, Siddiqui S. Non-HDL cholesterol versus Apolipoprotein B in the identification of dyslipidemic phenotypes associated with cardiovascular risk in type 2 diabetic dyslipoproteinemia. Diabetes Metab Syndr: Clin Res Rev 2007; 1: 29-36.
11. Stein EA, Sniderman AD, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 2005; 96(suppl): 36K-43K.
12. Contois JH, McConnell JP, Sethi AA et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 407-19.